Abstract:Objective: This study was conducted to develop a population phannacokinetic (PopPK) model for vancomycin and to detect the significant covariates that influence the PopPKs to facilitate individualized therapy for Chinese pediatric patients. Methods: Patients <= 10 years old who received vancomycin for >= 72 hours between 2007 and 2010 were analyzed using a nonlinear mixed effects modeling approach (NONMEM). A one-compartment model with first-order elimination was chosen to depict the data. Stepwise covariate modeling (SCM) was employed to detect significant covariates and obtain a final model. Internal validation methods, including bootstrapping and visual predictive checks (VPC), were applied to evaluate the robustness and predictive power of the final model. Results: The analysis included 54 pediatric inpatients with 128 serum concentration samples. The mean age (range) was 124.30 (1.29 - 541.4) weeks, the mean weight was 10.36 (1.4 - 33.5) kg, and the mean baseline serum creatinine (Scr) level was 0.39 (0.15 - 1.32) mg/dL. Pneumonia was the most common indication for vancomycin therapy (33.33%), followed by bacteremia (25.93%), and meningitis (22.22%). A PopPK model of vancomycin in Chinese pediatric patients was developed. Postnatal age (PNA) significantly affected the vancomycin clearance (CL) of pediatric patients, and the influence was described using the sigmoid maximum effect (E-max) model. The effect of body weight (WT) on CL and volume of distribution (V) was investigated using an allometric scaling equation. The final model parameters were CL(L/h) = 11.75x[PNA(0.4672)/ (PNA(0.4672)+33.3(0.4672))] X (WT/70)(0.75)xe(0.362) and V(L) = 54.49xWT/70xe(0.6711). The model evaluation results suggested robustness and good predictability of the final model. Conclusion: A PopPK model of vancomycin for Chinese pediatric patients was developed in this study. The significant covariates distinguished in the final model can provide helpful information to facilitate individualized therapy for Chinese pediatric patients.

Establishment and validation of vancomycin population pharmacokinetic model for intensive care unit patients

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

[Population Pharmacokinetics of Vancomycin from Severe in Patients with Lower Respiratory Tract Infection].

External validation of vancomycin population pharmacokinetic models in ten cohorts of infected Chinese patients

Population Pharmacokinetic of Vancomycin Administered by Continuous Infusion in Critically Ill Patients

Population Pharmacokinetics Model of Vancomycin in Chinese Adult Patients

Population Pharmacokinetics and Dosing Simulation of Vancomycin Administered by Continuous Injection in Critically Ill Patient

Population Pharmacokinetics Of Vancomycin In Chinese Pediatric Patients

Population Pharmacokinetics of Vancomycin and Prediction of Pharmacodynamics in the Chinese People

Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis

Evaluation of the population pharmacokinetic models of vancomycin in geriatric patients

Population Pharmacokinetics Modeling of Vancomycin Among Chinese Infants With Normal and Augmented Renal Function

Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections.

Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients

Population Pharmacokinetics and Pharmacodynamics Analysis of Vancomycin in Patients with Severe Lower Respiratory Tract Gram-Positive Infections

Towards Precision Dosing of Vancomycin in Critically Ill Patients: an Evaluation of the Predictive Performance of Pharmacometric Models in ICU Patients.

Initial Dosage Regimens Of Vancomycin For Chinese Adult Patients Based On Population Pharmacokinetic Analysis

Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance

Vancomycin Population Pharmacokinetic Modeling in Children Using Bayesian Estimation and a Non Parametric Approach

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Vancomycin population pharmacokinetic models: Uncovering pharmacodynamic divergence amid clinicobiological resemblance